ClavystBio
Overview
ClavystBio is a life sciences investor and venture builder established by Temasek that invests in and partners with founders to launch and grow global companies from Singapore. Its focus spans therapeutics, digital health, and medtech, with an emphasis on first-in-class science and technology.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Engine Biosciences | Oct 2023 | Series A Extension | Co-investor |
| Rejoni, Inc. | Jun 2026 | VC Round | Co-investor |
| Respiree | Sep 2026 | Series A Extension | Lead |
| Nuevocor | May 2025 | Series B | Co-investor |
| Sunbird Bio | Oct 2024 | Early Funding | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is ClavystBio based?
ClavystBio is headquartered in Singapore, Singapore.
When was ClavystBio founded?
ClavystBio was founded in 2022.
How many portfolio companies does ClavystBio have?
ClavystBio has 14 portfolio companies in Caplight's dataset.
What are some companies in ClavystBio's portfolio?
Portfolio companies visible on Caplight include Engine Biosciences, Rejoni, Inc., Respiree, Nuevocor, Sunbird Bio.
What was ClavystBio's most recent investment shown here?
ClavystBio's most recent investment in this portfolio sample was in Respiree in 2026.
What sectors does ClavystBio focus on?
ClavystBio focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Real Estate & PropTech, Enterprise Software, Frontier & Industrial Tech.
What company stages does ClavystBio focus on?
ClavystBio typically invests at the Early stage.
What is ClavystBio's AUM?
ClavystBio's assets under management are estimated between $220.0M and $220.0M.